Topic

mRNA Vaccines

Fillmore has investigated the efficacy and safety of mRNA vaccines in high-risk and previously infected populations. His research demonstrates that patients with plasma cell disorders, including multiple myeloma, experience higher rates of breakthrough SARS-CoV-2 infections despite receiving booster doses. Additionally, his work indicates that individuals with prior COVID-19 infections may face a transient increase in hospitalization rates following a second mRNA vaccine dose, primarily due to vaccine side effects in older adults with significant comorbidities.

U.S. Veterans and VA Data 3 COVID-19 3 Vaccine Effectiveness 3 Retrospective Cohort Study 2 Electronic Health Records 2 Multiple Myeloma 2 Matched Cohort Study 2 Severe COVID-19 2 Monoclonal Gammopathy of Undetermined Significance 2 Fine-Gray Models 1 Systemic Cancer Therapy 1 ICD-10 Coding 1

Publications (3)

2023

Even after SARS-CoV-2 booster, there is increased COVID-19 breakthrough infection in patients with plasma cell disorders.

Nathanael R. Fillmore, Jennifer La, Julie Tsu-Yu Wu, June K. Corrigan, Westyn Branch-Elliman, Paul Monach, Mary T. Brophy, Nhan V. Do, Nikhil C. Munshi

Blood Advances7(21), 6767-6770

U.S. Veterans and VA Data Retrospective Cohort Study Electronic Health Records Multiple Myeloma COVID-19

2022

Increased COVID-19 breakthrough infection risk in patients with plasma cell disorders.

Jennifer La^†, Julie Tsu-Yu Wu^†, Westyn Branch-Elliman, Linden Huhmann, Summer S. Han, Mary Brophy, Nhan V. Do, Albert Y. Lin, Nathanael R. Fillmore^‡, Nikhil C. Munshi^‡^† Equal first authorship · ^‡ Equal senior authorship

Blood140(7), 782-785

U.S. Veterans and VA Data Electronic Health Records Multiple Myeloma COVID-19 Vaccine Effectiveness

2022

Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study.

Lucy L. Li^†, Chunlei Zheng^†, Jennifer La, Nhan V. Do, Paul A. Monach, Judith M. Strymish, Nathanael R. Fillmore^‡, Westyn Branch-Elliman^‡^† Equal first authorship · ^‡ Equal senior authorship

Vaccine40(8), 1082-1089

U.S. Veterans and VA Data Retrospective Cohort Study COVID-19 Vaccine Effectiveness mRNA Vaccines